Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) announced today that Eisai and Nitto Denko Corporation (Headquarters: Osaka, President: Masamichi Takemoto) signed a joint development agreement on a transdermal adhesive preparation of Aricept
tablet is currently indicated for mild to moderate Alzheimer's disease. With this agreement, the companies will jointly develop a transdermal patch formulation of Aricept
, using Nitto Denko's proprietary technology.
Nitto Denko, a top maker of optical films for liquid crystal displays, is engaged in a broad range of businesses ranging from electronic materials to medical materials. In particular, Nitto Denko is a global pioneer and expert in the development of transdermal delivery-type medical products, and has development and production sites in Japan and the U.S.A. In the U.S., the company operates a subsidiary Aveva Drug Delivery Systems, Inc. Nitto Denko has well-established technologies for the outstanding design of safe and stable delivery systems, including the synthesis of adhesives that are optimal for controlled release of drugs from the patches.
Eisai has been improving the product value of globally marketed Aricept
by proactively adding new indications and formulations to satisfy the medical needs of Alzheimer's disease patients. Eisai will continue its efforts to raise the level of benefits provided to patients by promoting development of a transdermal adhesive preparation with this agreement and offering further convenience to Alzheimer's disease patients and their caregivers.